Tilmanocept
- Generic Name
- Tilmanocept
- Brand Names
- Lymphoseek
- Drug Type
- Small Molecule
- CAS Number
- 1185986-76-8
- Unique Ingredient Identifier
- MDU8BQ474H
- Background
Tilmanocept is under investigation in clinical trial NCT03241446 (Pharmacokinetics and Dosimetry of Tc 99m Tilmanocept Following a Single Intravenous Dose Administration in Male and Female Subjects Diagnosed With Rheumatoid Arthritis (RA)).
- Associated Conditions
- Breast Cancer, Melanoma, Oral Cancer
Lymphoseek® as Lymphoid Tissue Targeting Agents in Colon Cancer(CNC)
- Conditions
- Colon CancerRectal Cancer
- Interventions
- First Posted Date
- 2013-07-18
- Last Posted Date
- 2021-06-23
- Lead Sponsor
- Maimonides Medical Center
- Target Recruit Count
- 16
- Registration Number
- NCT01902953
- Locations
- 🇺🇸
Maimonides medical Center, Brooklyn, New York, United States
Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes
- First Posted Date
- 2010-04-19
- Last Posted Date
- 2013-06-17
- Lead Sponsor
- Navidea Biopharmaceuticals
- Target Recruit Count
- 163
- Registration Number
- NCT01106040
- Locations
- 🇺🇸
The Ohio State University, Columbus, Ohio, United States
🇺🇸Breast Care Specialists, Columbus, Ohio, United States
🇺🇸University Hospitals Cleveland, Cleveland, Ohio, United States
Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma
- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC)
- First Posted Date
- 2009-06-01
- Last Posted Date
- 2014-08-08
- Lead Sponsor
- Navidea Biopharmaceuticals
- Target Recruit Count
- 101
- Registration Number
- NCT00911326
- Locations
- 🇺🇸
University of Alabama, Birmingham, Birminham, Alabama, United States
🇺🇸University of Miami, Sylvester Comprehensive Cancer Center, Miami, Florida, United States
🇺🇸San Diego VA Hospital, San Diego, California, United States
Trial of Lymphoseek in Intraoperative Localization of Lymph Nodes in Breast Cancer and Melanoma
- First Posted Date
- 2008-05-05
- Last Posted Date
- 2013-06-17
- Lead Sponsor
- Navidea Biopharmaceuticals
- Target Recruit Count
- 186
- Registration Number
- NCT00671918
- Locations
- 🇺🇸
Mark Faries, M.D., Santa Monica, California, United States
🇺🇸Stephen Povoski, M.D., Columbus, Ohio, United States
🇺🇸Steve Martinez, M.D., Sacramento, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.